Skip to main content
. Author manuscript; available in PMC: 2011 Jul 12.
Published in final edited form as: Vaccine. 2010 May 21;28(31):5017–5022. doi: 10.1016/j.vaccine.2010.05.018

Table 1.

Type-specific and J14 antibodies evoked in rabbits by hexavalent and hexavalent-J14 vaccines

Rabbit #2 ELISA titer against1:
Hexa Hexa-J14 J14 M24.2 M5.2 M6.6 M19.2 M1-0.2 M3.2
Pre-pool <200 <200 <200 <200 <200 <200 <200 <200 <200
#1 51,200 51,200 <200 6,400 6,400 25,600 6,400 3,200 1,600
#2 102,400 102,400 <200 25,600 12,800 51,200 6,400 12,800 6,400
#3 204,800 204,800 <200 25,600 25,600 51,200 6,400 12,800 12,800
Pre-pool <200 <200 <200 <200 <200 <200 <200 <200 <200
#4 51,200 102,400 3,200 12,800 12,800 51,200 6,400 6,400 3,200
#5 51,200 51,200 1,600 6,400 6,400 25,600 3,200 3,200 6,400
#6 204,800 204,800 1,600 25,600 25,600 51,200 6,400 6,400 6,400
1

ELISA antigens were the purified recombinant vaccine proteins (hexavalent and hexavalent-J14), the unconjugated synthetic J14 peptide or recombinant dimeric peptides that copied the type-specific components of the hexavalent hybrid protein.

2

Rabbits #1–#3 were immunized with 200μg recombinant hexavalent protein and rabbits #4–#6 received i.m. injections of 200μg of recombinant hexavalent-J14 protein at times 0, 4 and 8 weeks. Serum was obtained 2 weeks after the final immunization.